{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:50:21Z","timestamp":1791478221967,"version":"4.3.4"},"reference-count":50,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Multivalent meningococcal conjugate vaccines are a significant focus for the scientific community in light of the WHO\u2019s mission to defeat meningitidis by 2030. Well-known meningococcal vaccines such as MenAfriVac, Nimenrix, Menveo, and MenQuadfi are licensed in various parts of the world and have been successful. Recently, the World Health Organization (WHO) qualified MenFive (meningococcal A, C, Y, W, and X) conjugate vaccine, further enhancing the battery of vaccines against meningitis. The antigenic nature of the current and new serogroups, the selection of carrier proteins, and the optimal formulation of these biomolecules are pivotal parameters for determining whether a biological preparation qualifies as a vaccine candidate. Creating appropriate quality control analytical tools for a complex biological formulation is challenging. A scoping review aims to identify the main challenges and gaps in analyzing multivalent vaccines, especially in the case of novel serogroups, such as X, as the limited literature addresses these analytical challenges. In summary, the similarities in polysaccharide backbones between meningococcal serogroups (C, Y, W sharing a sialic acid backbone and A, X sharing a phosphorous backbone) along with various conjugation chemistries (such as CNBr activation, reductive amination, CDAP, CPIP, thioether bond formation, N-hydroxy succinimide activation, and carbodiimide-mediated coupling) resulting into a wide variety of polysaccharide -protein conjugates. The challenge in analyzing carrier proteins used in conjugation (such as diphtheria toxoid, tetanus toxoid, CRM diphtheria protein, and recombinant CRM) is assessing their purity (whether they are monomeric or polymeric in nature as well as their polydispersity). Additional analytical challenges include the impact of excipients, potential interference from serogroups, selection and establishment of standards, age-dependent behavior of biomolecules indicated by molecular size distributions, and process-driven variations. This article explains the analytical insights gained (polysaccharide content, free saccharide, free proteins, MSD) during the development of the MenFive vaccine and highlights the crucial gaps and challenges in testing.<\/jats:p>","DOI":"10.3390\/vaccines12111227","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T04:51:33Z","timestamp":1730177493000},"page":"1227","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Analytical Challenges in Novel Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W, X)"],"prefix":"10.3390","volume":"12","author":[{"given":"Pankaj","family":"Sharma","sequence":"first","affiliation":[{"name":"Serum Institute of India Pvt Ltd., Pune 411 028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Kale","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt Ltd., Pune 411 028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Phugare","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt Ltd., Pune 411 028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil Kumar","family":"Goel","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt Ltd., Pune 411 028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Gairola","sequence":"additional","affiliation":[{"name":"Serum Institute of India Pvt Ltd., Pune 411 028, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2165\/11209580-000000000-00000","article-title":"Meningococcal Quadrivalent (Serogroups A, C, W135 and Y) Tetanus Toxoid Conjugate Vaccine (Nimenrix)","volume":"72","author":"Croxtall","year":"2012","journal-title":"Drugs"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/11204790-000000000-00000","article-title":"Meningococcal Quadrivalent (Serogroups A, C, W135, and Y) Conjugate Vaccine (Menveo)","volume":"24","author":"Deeks","year":"2010","journal-title":"Biodrugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1086\/339010","article-title":"Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana","volume":"185","author":"Gagneux","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.4269\/ajtmh.2009.80.619","article-title":"Epi-demiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya","volume":"80","author":"Mutonga","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/511646","article-title":"Meningococcal meningitis: Unprecedented Incidence of Serogroup X-related Cases in 2006 in Niger","volume":"44","author":"Nicolas","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7815","DOI":"10.1016\/j.vaccine.2020.10.017","article-title":"Quantitation of novel pentavalent meningococcal polysaccharide conjugate vaccine (Men A-TT, Men C-CRM, Men Y-CRM, Men W-CRM, Men X-TT) using sandwich ELISA","volume":"38","author":"Phugare","year":"2020","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.biologicals.2013.12.001","article-title":"Process development and immunogenicity studies on a serogroup \u2018X\u2019 Meningococcal polysaccharide conjugate vaccine","volume":"42","author":"Chilukuri","year":"2014","journal-title":"Biologicals"},{"key":"ref_8","first-page":"586","article-title":"Optimizing protection against meningococcal disease","volume":"49","author":"Reisinger","year":"2010","journal-title":"ClinPediatr"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1042\/CS20090513","article-title":"Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease","volume":"118","author":"Hill","year":"2010","journal-title":"Clin. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2147\/IDR.S159952","article-title":"Meningococcal group B vaccine for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B","volume":"12","author":"Raguindin","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1080\/21645515.2018.1451810","article-title":"Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development","volume":"14","author":"Dretler","year":"2018","journal-title":"Hum. Vaccin. Immun. Other"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ab.2013.08.001","article-title":"Meningococcal X polysaccharide quantification by high-performance anion-exchange chromatography using synthetic N-acetylglucosamine-4-phosphate as standard","volume":"442","author":"Micoli","year":"2013","journal-title":"Anal. Biochem."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Bolgiano, B., Moran, E., Beresford, N.J., Gao, F., Care, R., Desai, T., Nordgren, I.K., Rudd, T.R., Feavers, I.M., and Bore, P. (2021). Evaluation of Critical Quality Attributes of a Pentavalent (A, C, Y, W, X) Meningococcal Conjugate Vaccine for Global Use. Pathogens, 10.","DOI":"10.3390\/pathogens10080928"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Pizza, M., Bekkat-Berkani, R., and Rappuoli, R. (2020). Vaccines against meningococcal diseases. Microorganisms, 8.","DOI":"10.3390\/microorganisms8101521"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.biologicals.2013.03.003","article-title":"Serogroup quantitation of multivalent polysaccharide and polysaccharide-conjugate meningococcal vaccines from China","volume":"41","author":"Cook","year":"2013","journal-title":"Biologicals"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1006\/biol.1997.0121","article-title":"A Simple and Rapid Method for Measuring Unconjugated Capsular Polysaccharide (PRP) of Haemophilus influenzae type b in PRP-tetanus toxoid conjugate vaccine","volume":"26","author":"Guo","year":"1998","journal-title":"Biologicals"},{"key":"ref_18","first-page":"259","article-title":"Quantification of free polysaccharide in meningococcal polysaccharide-diphtheria toxoid conjugate vaccines","volume":"103","author":"Lei","year":"2000","journal-title":"Dev. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1016\/j.vaccine.2017.03.066","article-title":"Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM197, DT and TT glycoconjugate vaccines","volume":"35","author":"Beresford","year":"2017","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jpba.2017.02.042","article-title":"Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever","volume":"139","author":"Giannelli","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kale, S., Phugare, S., Sharma, P., Goel, S., and Gairola, S. (2023). Method Development and Validation of Unbound Saccharide content (Serogroup A, C, Y, W, X) in Novel Pentavalent Meningococcal Polysaccharide Conjugate Vaccine with two different carrier proteins. J. Pharm. Biomed. Anal., 236.","DOI":"10.1016\/j.jpba.2023.115679"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0264-410X(98)00166-2","article-title":"A routine high-performance size-exclusion chromatography to determine molecular size distribution of Haemophilus influenzae type b conjugate vaccines","volume":"17","author":"Parisi","year":"1999","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1042\/BA20020066","article-title":"Evaluation of meningococcal C oligosaccharide conjugate vaccines by size-exclusion chromatography\/multi-angle laser light scattering, Biotechnol","volume":"36","author":"Jumel","year":"2002","journal-title":"Appl. Biochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9404068","DOI":"10.1155\/2016\/9404068","article-title":"A High-Throughput Size Exclusion Chromatography Method to Determine the Molecular Size Distribution of Meningococcal Polysaccharide Vaccine","volume":"2016","author":"Khan","year":"2016","journal-title":"Int. J. Anal. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"124048","DOI":"10.1016\/j.jchromb.2024.124048","article-title":"Molecular size distribution in pentavalent (A, C, Y, W, X) meningococcal polysaccharide conjugate vaccine by HPSEC-UV-MALS-RI method- a conceivable stability indicating parameter","volume":"1236","author":"Sharma","year":"2024","journal-title":"J. Chromatogr. B"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","article-title":"Neisseria meningitidis: Biology, Microbiology, and Epidemiology","volume":"799","author":"Rouphael","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"B71","DOI":"10.1016\/j.vaccine.2009.04.070","article-title":"Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis","volume":"27","author":"Stephens","year":"2009","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1016\/j.vaccine.2006.03.034","article-title":"A review of vaccine research and development: Meningococcal disease","volume":"24","author":"Girard","year":"2006","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.inf.0000148928.10057.86","article-title":"Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W135) Meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in 2-to 10-year-old children","volume":"24","author":"Pichichero","year":"2005","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1517\/14712598.5.11.1475","article-title":"Meningococcal conjugate vaccines","volume":"5","author":"Pichichero","year":"2005","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/000992280504400603","article-title":"Meningococcal conjugate vaccine in adolescents and children","volume":"44","author":"Pichichero","year":"2005","journal-title":"Clin. Pediatr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1097\/01.inf.0000147642.85129.05","article-title":"Global epidemiology of meningococcal disease and vaccine efficacy","volume":"23","author":"Pollard","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_33","first-page":"1475","article-title":"Changes in Neisseria meningitidis disease","volume":"5","author":"Cohn","year":"2005","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: Implications for prevention of meningococcal disease","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis."},{"key":"ref_35","first-page":"53","article-title":"La m\u00e9ningite c\u00e9r\u00e9bro-spinale en Afrique","volume":"28","author":"Lapeyssonnie","year":"1963","journal-title":"Bull. WHO"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4161\/hv.19619","article-title":"Development of a group A meningococcal conjugate vaccine, MenAfriVacTM","volume":"8","author":"Frasch","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1586\/14760584.8.2.227","article-title":"Quality-control issues and approaches in vaccine development","volume":"8","author":"Bernard","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s40121-022-00609-9","article-title":"Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review","volume":"11","author":"Marshall","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_39","unstructured":"WHO (2004). Technical Report, Series No. 924, Recommendations for Producing and Controlling Meningococcal Group C Conjugate Vaccines."},{"key":"ref_40","unstructured":"(2011). Recommendations to Assure Group A Meningococcal Conjugate Vaccines\u2019 Quality, Safety and Efficacy (Standard No. WHO_TRS_962)."},{"key":"ref_41","unstructured":"(2011). Part, C. Clinical Evaluation of Group. C Meningococcal Conjugate Vaccines (Revised 2007) (Standard No. WHO_TRS_963)."},{"key":"ref_42","unstructured":"WHO (1976). Technical Report Series, No. 594, Requirements for Meningococcal Polysaccharide Vaccine (Requirements for Biological Substances No. 23), WHO Expert Committee on Biological Standardization. Twenty-Seventh Report, Annex 2."},{"key":"ref_43","unstructured":"WHO (1978). Technical Report Series, No. 626, Requirements for meningococcal polysaccharide vaccine (Requirements for Biological Substances No. 23), WHO Expert Committee on Biological Standardization. Twenty-Ninth Report, Annex 2 Addendum."},{"key":"ref_44","unstructured":"WHO (1981). Technical Report Series No. 658, Requirements for meningococcal polysaccharide vaccine (Requirements for Biological Substances No. 23), WHO Expert Committee on Biological Standardization. Thirty-First Report, Annex 6."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"19077","DOI":"10.1073\/pnas.1314476110","article-title":"Costantino: Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X","volume":"110","author":"Micoli","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1016\/j.vaccine.2012.08.021","article-title":"Relative stability of meningococcal serogroup A and X polysaccharides","volume":"30","author":"Berti","year":"2012","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ab.2004.12.002","article-title":"Determination of meningococcal polysaccharides by capillary zone electrophoresis","volume":"338","author":"Lamb","year":"2005","journal-title":"Anal. Biochem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jim.2014.03.020","article-title":"Development of four sandwich ELISAs for quantitation of capsular polysaccharides from Neisseria meningitidis serogroups A, C, W and Y in multivalent vaccines","volume":"407","author":"Reyes","year":"2014","journal-title":"J. Immunol. Methods"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1021\/ac5003933","article-title":"Quantification of each serogroup polysaccharide of Neisseria meningitidis in A\/C\/Y\/W--DT Conjugate vaccine by High Performance Anion Exchange Chromatography-PulsedAmperometric Detection analysis","volume":"86","author":"Gudlavalleti","year":"2014","journal-title":"Anal. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1128\/IAI.66.5.1891-1897.1998","article-title":"Synthesis and Characterization of Lipooligosaccharide-Based Conjugates as Vaccine Candidates forMoraxella (Branhamella)catarrhalis","volume":"66","author":"Guo","year":"1998","journal-title":"Infect. Immun."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/11\/1227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:22:40Z","timestamp":1760113360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/11\/1227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["vaccines12111227"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12111227","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]}}}